Third-Line chemotherapy for metastatic Urothelial Cancer : a retrospective observational study by G. Di Lorenzo et al.
icine®
ONAL STUDYMed
OBSERVATIThird-Line Chemotherapy for Metastatic Urothelial Cancer
A Retrospective Observational Study, MD, Teresa Bellelli, Romano, MD,
hDGiuseppe Di Lorenzo, MD, PhD, Carlo Buonerba
Vittorino Montanaro, MD, Matteo Ferro, MD, PD
(HR: 4.37; 95% CI¼ 1.95–9.77; P < 0.01).
We observed a significantly longer overall survival in patients
receiving single-agent cyclophosphamide, with few grade 3 to 4
patients receiving dif
portion of patients rece
respect to those treated
Editor: Marco Alves.
Received: October 6, 2015; revised: November 4, 2015; accepted:
November 19, 2015.
From the Medical Oncology, University Federico II of Naples, Naples (GDL,
CB, DR, SDP); Medical Oncology, Hospital ‘‘San Luca,’’ Vallo della
Lucania, Salerno (TB); ASL Napoli 3 SUD, Naples (CR); Istituto Oncologico
del Sud, Naples (VM); Division of Urology, European Institute of Oncology,
Milan (MF, ODC); Division of Urology, Hospital ‘‘San Luca,’’ Vallo della
Lucania, Salerno (AB); Department of Emergency and Organ Transplanta-
tion, Urology and Kidney Transplantation Unit, University of Bari, Bari, Italy
(GL); Department of Urology, ‘‘Iuliu Hatieganu’’ University ofMedicine and
Pharmacy, Cluj-Napoca, Romania (ODC); and Department of Medicine,
Section of Hematology-Oncology, University of Alabama, Birmingham
School of Medicine, Birmingham, AL (GS).
Correspondence: Giuseppe Di Lorenzo, University Federico II of Naples, Via
Pansini, 5 – Naples, Italy (e-mail: giuseppedilorenzoncol@hotmail.com).
GDL and CB equally contributed to this study.
Funding: this work was partially supported by LILT (Lega Italiana alla Lotta
ai Tumori) - Sez. Napoli.
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution-NoDerivatives License 4.0, which allows for redistribution,
commercial and non-commercial, as long as it is passed along unchanged
and in whole, with credit to the author.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002297
Medicine  Volume 94, Number 51, December 2015MD, Concetta
sa, MD, DarioGiuseppe Lucarelli, MD, PhD, Ottavio De Cobelli, M
Abstract: The prognosis of locally advanced (T3/T4 or N1) and
metastatic disease urothelial carcinoma is poor. In this retrospective
study, we reviewed data about patients receiving third-line chemother-
apy for metastatic disease, in view of the lack of data in this setting.
We retrospectively analyzed medical records of patients with a
pathologic diagnosis of urothelial carcinoma treated with systemic
chemotherapy for metastatic disease at 4 participating Institutions
between January, 2010, and January, 2015. Cox proportional hazards
regression was used to evaluate the association of the chemotherapy
agent used versus others with overall survival, adjusted for 5 externally
validated prognostic factors in advanced urothelial carcinoma.
Of 182 patients that received first-line chemotherapy/adjuvant
chemotherapy as defined above, 116 patients (63.73%) received sec-
ond-line salvage treatment. Fifty-two patients were finally included in
this analysis, whereas 9 were excluded due to missing data. Third-line
chemotherapy was based on cyclophosphamide, platinum, vinflunine,
taxanes, and gemcitabine in 16, 12, 11, 10, and 3 patients, respectively.
Median PFS (progression-free survival) and OS (overall survival) of the
population were 13 (10–17) and 31 (28–36) weeks. Single-agent
cyclophosphamide was associated with a PFS of 18 (13–22) and an
OS of 38 (33–41) weeks, whereas platinum-based combinations were
associated with a PFS of 5 weeks and an OS of 8 weeks. Multivariate
analysis showed improved survival in patients treated with cyclopho-
sphamide (hazard ratio (HR)¼ 0.42; 95% CI: 0.20–0.89; P¼ 0.025)
and a worse survival in those treated with platinum-based regimens, Alfonso Beninca Ribera, MD,
, Guru Sonpavde, MD, and Sabino De Placido, MD
toxicities. Further studies should assess the efficacy of metronomic
single-agent cyclophosphamide in advanced lines of treatment, as it may
yield a survival benefit with low costs and no detrimental effects on
quality of life.
(Medicine 94(51):e2297)
Abbreviations: BCA = bias-corrected and accelerated, HR =
hazard ratio, IQR = interquartile range, MVAC = methotrexate,
vinblastine, adriamycin, and cisplatin, OS = overall survival, PFS =
progression-free survival.
INTRODUCTION
I n 2012, an estimated 429,800 new cases of urothelial bladdercancer and 165,100 related deaths were reported worldwide.1
Bladder carcinoma is associated with multiple risk factors,
which include smoking, occupational exposure, and diabetes,
whereas fruit consumption has been associated with a decreased
risk of having the disease.2,3 The prognosis of locally advanced
(T3/T4 or N1)4 and metastatic disease5,6 is poor, with few
approved therapeutic options. Platinum-based chemotherapy is
the standard first-line treatment in patients with recurrent dis-
ease and is associated with a median survival of 14 to 15
months.5 In spite of a wealth of systemic options that showed
activity after cisplatin failure,7 there is no universal consensus
about the optimal salvage agent in this setting. Vinflunine is
approved in Europe but not in the US on the basis of the results
of a phase 3 trial that demonstrated its limited efficacy versus
best supportive care alone after cisplatin failure with a signifi-
cant survival improvement of 2.5 months in the eligible, but not
in the intention-to-treat population (6.8 vs 4.3).6 Taxanes are
also commonly used in cisplatin-pretreated patients, either
alone or in combination with a variety of agents, such as
gemcitabine, cyclophosphamide, ifosfamide, and epirubicin,
with a meta-analysis indicating better efficacy of taxane-based
combination chemotherapy versus single-agent taxane.8
In this retrospective, multi-institutional study, we observed
patients at the time they received third-line systemic treatment
for metastatic disease. Patients that were eligible for this study
included (1) those that had relapsed< 12 months since the end
of adjuvant chemotherapy and had then received a single line of
treatment for metastatic disease; (2) patients who had
relapsed> 12 months since the end of adjuvant chemotherapy
and had received 2 lines of treatment for metastatic disease and
(3) patients who had not received adjuvant chemotherapy and
had received 2 lines of treatment for metastatic disease. The
primary objective of our analysis was to assess the overall
survival of the population and the survival differences inferent third-line treatments. The pro-
iving third-line systemic treatment with
with first-line therapy was also assessed,
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along with measures of third-line chemotherapy toxicity
and efficacy.
PATIENTS AND METHODS
Inclusion Criteria
We retrospectively analyzed medical records of patients
with a pathologic diagnosis of urothelial carcinoma treated with
systemic chemotherapy for metastatic disease at 4 participating
Italian Institutions between January, 2010, and January, 2015.
Patients receiving at least 1 cycle of first-, second- and third-line
systemic treatment for metastatic disease were included in this
analysis. Salvage treatment administered if a patient had
relapsed< 12 months since the end of adjuvant chemotherapy
was considered as second-line treatment, whereas systemic
treatment administered to a patient with metastatic disease
who had relapsed> 12 months since the end of adjuvant
chemotherapy was considered as first-line treatment, as dis-
cussed by Sonpavde et al.8 In order to avoid biases due to data
incompleteness, the following data were required for inclusion
in this retrospective study: overall survival, albumin levels,
hemoglobin, performance status, time from prior chemotherapy,
third-line chemotherapy received, and presence of liver metas-
tasis. The protocol was notified to the Internal Institutional
Review Board of the participating Institutions. Approval of
retrospective observational studies by the ethics committee is
not required according to the Italian law. This study was
undertaken in accordance with principles of the Declaration
of Helsinki and Good Clinical Practice guidelines.
Retrieved Data
Demographic data of eligible patients were retrieved along
with clinical and histologic characteristics at the time of the
third-line chemotherapy such as albumin levels, hemoglobin,
performance status, prior chemotherapy, time from prior che-
motherapy received, presence of liver metastasis. The following
data were extracted about previous chemotherapy: duration of
treatment, number of cycles, time from treatment initiation to
third-line chemotherapy. Albumin levels, hemoglobin, and per-
formance status (PS) were required to be assessed within 15
days before third-line chemotherapy initiation. The presence of
liver metastasis had to be assessed with CT scan within 30 days
before third-line treatment initiation. Data about overall survi-
val, progression, response, grade 3 to 4 toxicity, and treatment
suspension/interruption associated with third-line treatment
were collected. Patients alive as of June 1, 2015, or who were
lost at follow-up were censored from the survival analysis.
Toxicity severity was defined according to the National Cancer
Institute common toxicity criteria (version 4.0), if applicable.
Response associated with treatment was assessed by the treating
physician using the RECIST criteria 1.0 according to Institu-
tional policy and was retrieved by the reviewed charts.
Data Analysis
Descriptive statistics and frequency counts were used to
summarize characteristics of the study population. Median
numbers were presented with interquartile ranges, unless speci-
fied otherwise (IQR). Progression was defined as objective
tumor progression or death from any cause and was calculated
using the Kaplan–Meier method. Progression-free survival
Di Lorenzo et al(PFS) was calculated from the date of study entry until pro-
gression or death. Overall survival (OS) was calculated from the
date of study entry until death from any cause and was
2 | www.md-journal.comcalculated using the Kaplan–Meier method. Comparison of
continuous variables between independent groups was per-
formed by the use of Mann–Whitney U test. Cox proportional
hazards regression was used to evaluate the association of the
chemotherapy agent used versus others with overall survival,
adjusted for 5 externally validated prognostic factors in
advanced urothelial carcinoma.9 Internal validation was per-
formed using bootstrap methods, with 95% bias-corrected and
accelerated (BCa) confidence intervals (CIs) and P values
calculated. All tests were 2-sided, and a value of P 0.05
was considered statistically significant. All calculations were
performed using SPSS IBM v. 23.
RESULTS
Study Population
Of 182 patients that received first-line chemotherapy/
adjuvant chemotherapy as defined above, 116 patients
(63.73%) received second-line salvage treatment and 61
(33.5%) received third-line chemotherapy for metastatic dis-
ease. Fifty-two patients were finally included in this analysis,
whereas 9 were excluded due to missing data (PS in 2 cases,
albumin in 5 cases, overall survival in 3 cases, hemoglobin in 1
case, and presence of liver metastasis in 6 cases). Of the 34
patients who had received prior adjuvant chemotherapy, 7 had a
recurrence within 12 months since the last cycle of adjuvant
chemotherapy and were treated with second-line chemotherapy,
whereas the remaining had a recurrence> 12 after the last cycle
of adjuvant chemotherapy and were treated with first-line
chemotherapy(Table 1). First-line chemotherapy was adminis-
tered in 45 patients, who received a median of 5 cycles (inter-
quartile range, 5–6), with a median treatment duration of 18
weeks (16–21,3). First-line treatment was platinum-based in
the majority of cases. Median time from the beginning of first-
line treatment to the beginning of third-line treatment was 47
weeks (range: 39–51). Seven patients did not receive first-line
treatment. These patients received a median of 6 cycles of
adjuvant chemotherapy (range: 5–6; median treatment
duration: 17; range 15–18). In these 7 patients, median time
from the beginning of adjuvant chemotherapy to the beginning
of third-line chemotherapy was 74 weeks (range: 67–74,5). All
patients received second-line chemotherapy (median number of
cycles, 4, range: 3–5; median treatment duration 15.5 weeks;
range: 12.8–18). The median time from the beginning of
second-line treatment to the beginning of third-line treatment
was 21.5 weeks (range 17.8–24). Second-line treatment was
based on vinflunine or docetaxel/paclitaxel. Doses and sche-
dules used for chemotherapy before third-line treatment are
detailed in Table 2.
Third-Line Chemotherapy
Third-line chemotherapy was based on cyclophosphamide,
platinum, vinflunine, taxanes, and gemcitabine in 16, 12, 11, 10,
and 3 patients, respectively. Cyclophosphamide was delivered
orally as a single agent at 100mg daily, with no interruption in all
patients, and it was cycled every 28 days. Four patients received
MVAC, consisting ofmethotrexate 20 to 30mg/m2 on day 1 or 2,
vinblastine 1.5 to 2 mg/m2 on day 2, doxorubicin 20 to 30 mg/m2
on day 2, and cisplatin 40 to 50mg/m2 or carboplatin AUC 3 to 4
on day 2, every 21 days. Alternatively, patients received cisplatin
Medicine  Volume 94, Number 51, December 201540 to 50mg/m2 /carboplatin AUC 3 to 4 in combination with
either methotrexate 20mg/m2 (5 patients) or gemcitabine
(800mg/m2) (3 patients). Of these, 4 patients had been treated
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TABLE 1. Characteristics of the Patients’ Population (N¼52)
Variable Median (Interquartile Range)
Albumin (g/dL) 3.5 3.2–3.7
Hemoglobin (g/dL) 10.4 9.2–11.0
Number of cycles of third-line chemotherapy 3.5 3–4
Time from last chemotherapy to initiation of third-line chemotherapy (weeks) 4 3–5
Variable Number of patients %
Performance status
0 5 9.6
1 27 51.9
2 20 38.4
Adjuvant/neoadjuvant chemotherapy
Yes 34 65.3
No 18 34.6
Liver metastasis
No 31 59.6
Yes 21 40.3
Bladder carcinoma 46 87%
Upper urinary tract cancers 6 13%
Recurrence within 12 months since end of neoadjuvant/adjuvant treatment
Yes 7 20.5
No 27 79.5
Patients receiving adjuvant/neoadjuvant chemotherapy!II line treatment 7 100
Adjuvant/neoadjuvant
Cisplatin-carboplatin/ gemcitabine 4 7.69
Gemcitabine 3 5.76
II line treatment
Paclitaxel/docetaxel 5 9.61
Vinflunine 2 3.84
Patients receiving adjuvant/neoadjuvant chemotherapy!I line
treatment !II line treatment
27 100
Adjuvant/neoadjuvant
Cisplatin-carboplatin/ gemcitabine 22 42.3
Gemcitabine 5 9.61
I line treatment
Paclitaxel/docetaxel 10 19.23
Cisplatin/gemcitabine 15 28.84
Gemcitabine 2 3.84
II line treatment
Paclitaxel/docetaxel 12 23.07
Vinflunine 15 28.84
Patients receiving I line treatment !II line treatment 28 100
I line treatment
Cisplatin-carboplatin/gemcitabine 14 26.92
Gemcitabine 4 7.69
II line treatment
Paclitaxel/docetaxel 7 13.46
Vinflunine 11 21.15
All patients
III line treatment
Cisplatin/carboplatin-based combination 12 23.07
Taxane 11 21.15
Vinflunine 10 19.23
Cyclophosphamide 16 30.76
Gemcitabine 3 5.76
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TABLE 2. Regimens Used Before Third-Line Chemotherapy
Regimens Used in the First Line/Perioperative Setting Doses and Schedules
Cisplatin/carboplatinþ gemcitabine Cisplatin (60–75mg /m2, day 1 every 3 weeks)
Carboplatin (AUC 4–5, day 1 every 3 weeks)
Gemcitabine (825–1100 mg/m2, day 1,8 every 3 weeks)
Single-agent gemcitabine Gemcitabine (1000–1100 mg/m2, day 1,8 every 3 weeks)
Regimens used in the second-line setting Doses and schedules
Single-agent Docetaxel Docetaxel (60–75 mg/m2, day 1 every 3 weeks)
Single-agent Paclitaxel Paclitaxel (60–80 mg/m2, day 1,8,15 every 4 weeks)
Di Lorenzo et al Medicine  Volume 94, Number 51, December 2015with2priorlinesofplatinum-basedchemotherapy.Vinfluninewas
delivered at 200 to 250mg/m2 every 3 weeks. Taxanes included
single-agent paclitaxel (150–170mg/2 3 weekly) (8 patients) or 3
weekly docetaxel 50 to 60mg/m2 (3 patients). Gemcitabine was
administered as a single-agent treatment at the dose of 800 to
1000mg/m2. No significant differences were found between
patients receiving different third-line treatments with respect to
previous first- and second-line treatment received (data not
shown). Median PFS and OS of the population were 13 (10–
17) and 31 (28–36) weeks. Single-agent cyclophosphamide was
associated with a PFS of 18 (13–22) and an OS of 38 (33–41)
weeks, whereas platinum-based combination was associated with
aPFSof5weeksandanOSof8weeks.Tenpatientswere judged to
have a radiological response by their treating physician. Only 1
patient reported a complete response, which was associated with
single-agent cyclophosphamide (Fig. 1). This patient was an 82-
yearoldmanwithapoorPSand lymphnode-onlydisease,whowas
treatedwithsingle-agentcyclophosphamidefor56weeksandwent
on to receive fourth-line treatment after progression. This patient
had previously received 6 cycles of platinum-based treatment as
first-line therapy formetastatic disease, but he had received only 4
administrations of weekly paclitaxel as second-line treatment.
Anecdotally, this patient also consumed quercetin, provided as
a courtesy of Quercegen Pharmaceuticals, during the entire treat-
ment duration. Outcomes and toxicity associated with third-line
chemotherapy are detailed in Tables 3 and 4, respectively.
Univariate and Multivariate Analysis for OS
VinflunineUnivariate analysis showed that PS (2–3 vs 0–1), albumin
levels ULN vs ULN, presence of liver metastasis (yes vs
no), use of taxanes and platinum compounds versus other agents
FIGURE 1. Complete radiologic response in a patient treated with 10
C¼ after 4 months).
4 | www.md-journal.comwere associated with a significantly worse survival in this
patient population. Lower hemoglobin levels and shorter time
from prior chemotherapy (continuous variable) were only mar-
ginally significant. At univariate analysis, we observed that
single-agent cyclophosphamide was associated with longer OS
(HR¼ 0.3), whereas platinum- and taxane-based chemotherapy
were associated with shorter OS (HR¼ 4.7 and HR¼ 2.5,
respectively) (Table 5 and Fig. 2). The better survival associated
with cyclophosphamide was also confirmed at multivariate
analysis (HR¼ 0.42; 95% CI: 0.20–0.89; P¼ 0.025)
(Table 6A). Platinum-based (Table 6B) but not taxane-based
(data not shown) chemotherapy was associated with a worse
survival at multivariate analysis. Bootstrapping performed to
internally validate the results showed that the 95% BCa CI for
the HR for OS of cyclophosphamide versus other agents was
0.13 to 0.82 (P¼ .07), while bootstrapped 95% BCa CI for the
HR for the use of cisplatin was (1.94–59.73; P¼ 0.01).
DISCUSSION
The setting of patients treated with third-line chemother-
apy for metastatic disease has been poorly explored in urothelial
carcinoma. One meta-analysis including 731 patients7 enrolled
in several phase II trials showed that progression-free survival
and overall survival were not influenced by the number of prior
treatment lines, which were calculated by including both adju-
vant and metastatic treatments. This analysis was not conceived
to capture the potential prognostic differences of patients
receiving prior treatment in the adjuvant versus the metastatic
Paclitaxel (180–200 mg/m2, day 1 every 3 weeks)
Vinflunine (270–300 mg/m2, day 1 every 3 weeks)setting or with different progression-free survival times after
adjuvant treatment, so it cannot be concluded that these patients
should be grouped together for prognostic purposes. As at the
0mg cyclosphosphamide daily. (A¼baseline; B¼ after 2 months;
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Outcome Associated With the Third-Line Regimen Used (N¼52)
Response
Number
of Patients Regimens
Duration of
Treatment
Weeks Cycles N PD SD PR CR
Median
Progression-free
survival (IQR)
Median
OS (IQR)
Whole population 52 See below 12 (7–17) 3 (2–3.8) 37 14 13 9 1 13 (10–17) 31 (28–36)
Cyclophosphamide 16 Single-agent cyclophosphamide 19 (15–21) 3.5 (3.4–4.5) 13 4 6 2 1 18 (13–22) 38 (33–41)
Platinum-based 12 Carboplatin-cisplatin
plus methotrexate/
gemcitabine MVAC
5 (5–6) 2 (1.5–2.5) 7 2 3 2 0 5 (4–6) 8 (8–12)
Taxane-based 11 Single-agent paclitaxel 12 (11.5–13) 3 (3–3.75) 7 3 2 2 0 14 (12–16) 28 (23–30)
Single-agent docetaxel
Vinflunine 10 Single-agent vinflunine 12 (10–17) 3 (3–4) 7 4 1 2 0 16 (10–20) 32 (31–37)
Gemcitabine 3 Single-agent gemcitabine 12 (8–12) 3(2–3) 3 1 1 1 0 14 (11–18) 33 (28–36)
CR¼ complete response; IQR¼ interquartile range; OS¼ overall survival; PD¼ progressive disease; PFS¼ progression-free survival; PR¼
Medicine  Volume 94, Number 51, December 2015 Third-Line Chemotherapy for Metastatic Urothelial Carcinomaparticipating Institutions patients relapsing< 12 months after
finishing adjuvant chemotherapy generally receive second-line
treatment, whereas patients relapsing >1 year after receiving
adjuvant treatment are generally candidates for a first-line
platinum-based regimen, we used a similar approach to define
the third-line setting in this study. This approach was consistent
with the findings of a retrospective analysis of 41 patients
receiving cisplatin-based first-line therapy for advanced urothe-
lial carcinoma following previous perioperative cisplatin-based
therapy. In this study, the median overall survival was 68 weeks,
with patients relapsing <52 weeks, between 52 and 104 weeks,
and after 104 since cisplatin completion showing a median
survival of 42, 70, and 162 weeks, respectively.10 Furthermore,
patients relapsing <12 months after completion of adjuvant
treatment are considered to be eligible for inclusion in a second-
line treatment salvage trial.11 In our retrospective study, we
found that approximately half of the patients treated with
second-line chemotherapy went on to receive third-line treat-
ment, which underlines the clinical meaningfulness of this
setting, and that third-line treatment was associated with a
median PFS of 13 weeks and a median OS of 31 weeks, which
is line with the median PFS of 2 to 4 months and the median OS
of 6 to 9 months reported in other published series.12–15 Only a
partial response; SD¼ stable disease.few studies have been specifically conducted in the third-line
setting in patients with urothelial carcinoma. Matsumoto16 et al
evaluated the efficacy of gemcitabine plus nedaplatin in 10
TABLE 4. Grade 3–4 Toxicities of Associated With Third-Line Tre
N
Overall
Grade 3
Toxicities Neutropenia Anemia Thrombocyt
Whole population 52 26 (50%) 18 (34.61%) 10 (19.23%) 11 (21.15
Cyclophosphamide 16 5 (31.25%) 0 (0%) 1 (6.25%) 2 (12.5%
Platinum-based 12 8(75%) 5 (41.66%) 4 (33.33%) 6 (50%
Taxanes 11 7 (63.63%) 7 (63.63%) 3 (27.27) 3 (27.27
Vinflunine 10 5 (50%) 5 (50%) 2 (20%) 0 (0%
Gemcitabine 3 1 (33.33%) 1 (33.33%) 0 (0%) 1 (33.33
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.patients with metastatic urothelial carcinoma who had been
previously treated with methotrexate, vinblastine, doxorubicin,
and cisplatin, followed by gemcitabine and paclitaxel. The
median overall survival was 8.8 months, whereas the median
progression-free survival was 5.0 months. Similarly, the use of
pegylated liposomal doxorubicin as a third-line chemotherapy
was associated with a median progression free survival and
overall survival of 4.1 and 6.3 months in 23 patients with
advanced urothelial carcinoma, whereas median time to pro-
gression and overall survival were 2 and 7.3 months, respect-
ively, in 13 patients treated with third-line gemcitabine.17,18
These results are consistent with those obtained in the overall
population of patients treated with third-line chemotherapy. In
our study, substantial heterogeneity in outcome was reported in
patients treated with different agents and regimens. Surpris-
ingly, patients receiving platinum-based combinations showed
a median survival of only 8 weeks (8–12). A detrimental effect
of platinum-based treatment was confirmed after controlling for
known prognostic factors, with an HR for death of 4.3 (95%
1.95–9.77). In 45 patients receiving accelerated MVAC (meth-
otrexate, vinblastine, adriamycin, and cisplatin) after platinum-
gemcitabine chemotherapy, median time to progression and
median overall survival were 5.8 and 14.2 months, respect-
ively.19 In the subset of 12 patients treated with platinum-based
chemotherapy analyzed in our work only 4 patients received
MVAC, whereas the remaining patients received a combination
atments
openia
Nausea/
Vomiting
Peripheral
Neuropathy Diarrhea Constipation Mucositis
%) 10 (19.23%) 7 (13.46%) 4 (7.69%) 13 (25%) 4 (7.69%)
) 1 (6.25%) 0 (0%) 1 (6.25%) 0 (0%) 0 (0%)
) 5 (41.66%) 4 (33.33%) 1 (8.33%) 4 (33.33%) 3 (25%)
%) 3 (27.27%) 2 (18.18%) 2 (18.18% 3 (27.27%) 1 (9.09%)
) 1 (10%) 1 (10%) 0 (0%) 3 (30%) 0 (0%)
%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
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TABLE 5. Univariable Analyses for Association of Variables With OS
Variable Type HR 95% CI P Value
PS 2–3 vs 0–1 1.90 1.05 3.45 0.03
Hemoglobin <10 vs 10 1.69 0.96 3.03 0.071
Albumin <LLN vs LLN 2.95 1.56 5.58 <0.01
Liver metastasis No vs Yes 0.43 0.24 0.78 <0.01
vs all Others cyclophosphamide 0.300 0.15 0.57 <0.01
Vinflunine 1.17 0.56 2.43 0.66
Taxanes 2.57 1.22 5.40 0.01
Platinum-based 4.75 2.31 9.76 <0.01
Time from last chemotherapy to third-line chemotherapy continuous variable 0.89 0.79 1.00 0.07
sur
Di Lorenzo et al Medicine  Volume 94, Number 51, December 2015of a platinum agent with gemcitabine or methotrexate.
Platinum-based chemotherapy was poorly tolerated, with grade
3 to 4 hematologic toxicities reported in 50% of patients,
whereas grade 3 to 4 nausea/vomiting, peripheral neuropathy,
and diarrhea/constipation were reported in 30 to 40% of
patients. The heterogeneity of the platinum-based chemother-
apy delivered along with the prior exposure to platinum agents
can explain the poor outcome observed in this subset of patients.
Conversely, patients treated with single-agent cyclophospha-
mide showed a median OS of 38 (33–41) weeks, which was
coupled with a median progression-free survival of 18 weeks.
Furthermore, patients treated with cyclophosphamide received
amedian of 3.5 cycles and showed a very low rate of grade 3 to 4
toxicities. Multivariate analysis of the use of cyclophosphamide
versus other agents showed a substantial reduction of the risk of
death, with an HR of 0.42; 95% CI: 0.20 to 0.89, after con-
trolling for established prognostic factors. To the best of our
CI¼ confidence interval; LLN¼ lower limit of normal; OS¼ overallknowledge, there are no previous reports on the use of single-
agent cyclophosphamide in urothelial carcinoma. In a phase I/II
trial on the combined use of paclitaxel with cyclophosphamide,
FIGURE 2. Overall survival in patients treated with different third-lin
6 | www.md-journal.comDi Lorenzo et al that showed that the maximum tolerated daily
dose of cyclophosphamide administered on days 1 to 7 in
combination with 175mg/m(2) of paclitaxel administered on
day 1 was only 50mg. This regimen was associated with a
median time to progression of 5 months (95% CI, 2 months–7.5
months) and a median OS of 8 months (95% CI, 4 months–14
months). In the 32 patients enrolled in the phase II part of the
trial, grade 1/2 vomiting, peripheral neuropathy, and neutrope-
nia were reported in 34%, 25%, and 31% of cases, respectively,
whereas grade 3 to 4 neutropenia was the most common severe
toxicity, occurring in 34.5% of patients. Another phase II trial
conducted in 46 patients with bladder or upper urinary tract
cancer treated with paclitaxelþ cyclophosphamide with the
same doses and schedule used by Di Lorenzo et al showed a
median time to progression of 3.0 months (95% CI 1.7–4.3
months), an objective response rate of 33.3%, and a median OS
of 6.3 months (95% CI 4.6–8.0 months). Differently from the
vival; PS¼ performance status.results by Di Lorenzo et al, grade  3 neutropenia occurred
only in 2 patients (6%), with one of them developing
febrile neutropenia. Interestingly, cyclophosphamide was daily
e regimens.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 6. AMultivariable Analyses for association of variables with OS: A (cyclophosphamide vs other treatments); B: (cisplatin vs
other treatments)
Variable Type HR 95% CI P Value
(A) Cyclophosphamide vs other treatments
PS 2–3 vs 0–1 1.40 0.76 0.27
2.58
Hemoglobin <10 vs10 1.68 0.85 0.13
3.31
Albumin <LLN vs LLN 1.67 0.77 0.19
3.61
Liver metastasis No vs Yes 0.43 0.22 0.01
0.87
Third-line treatment Cyclophosphamide vs other regimen 0.42 0.20 0.02
0.89
Time from last chemotherapy to third-line chemotherapy Continuous variable 0.93 0.82 0.32
(B) Cisplatin vs other treatments
PS 2–3 vs 0–1 0.95 0.70–2.87 0.88
Hemoglobin .<10 vs10 1.42 0.70–2.87 0.32
Albumin <LLN vs LLN 1.72 0.81–3.64 0.15
Liver metastasis No vs Yes 0.31 0.15–0.62 <0.01
Third-line treatment Platinum-based vs others 4.37 1.95–9.77 <0.01
Time from last chemotherapy to third-line chemotherapy Continuous variable 0.91 0.79–1.05 0.21
val;
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apparent increased toxicity. This finding is consistent with the
results obtained in our series, which showed an excellent safety
and efficacy profile for continuous metronomic cyclophospha-
mide. The absence of any concomitant treatment allowed us to
double the dose (100mg) used with respect to published trials.
Metronomic cyclophosphamide, which has been tested in
several solid tumors, including breast, prostate, and bladder
cancer, exerts a potent anti-angiogenic activity in preclinical
models.20,21 Furthermore, it may also contribute to controlling
tumor progression through an immunostimulatory effect, which
induces a reduction in circulating regulatory T cells (Treg),
leading to restoration of natural killer cell cytotoxicity, and
peripheral T-cell proliferation.22 Of note, we were intrigued by
a complete and durable response achieved with single-agent
cyclophosphamide in an 82-year old man, who also consumed
quercetin supplements. Although quercetin has been exten-
sively investigated in preclinical models of various types of
cancer (eg leukemia),23 and also in murine models of breast
cancer in combination with cyclophosphamide,24 there is a lack
of clinical data about its effects if used in combination with
chemotherapy agents, and additional studies are required to
define its potential role in cancer patients. The major strength of
our study includes the selection of patients treated in a poorly
explored setting.
Limitations typical of retrospective studies apply to our
work. Chemotherapy regimens were not administered accord-
ing to a protocol defining doses, schedules, dose reduction
algorithms, and so on. Analyzing differences in outcomes
associated with distinct treatments in a nonrandomized study
HR¼ hazard ratio; LLN¼ lower limit of normal; OS¼ overall surviis biased by a number of imbalances between the subgroups
considered that can only be partially taken into account by
using multivariate analysis. In this regard, it must be noted that
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.the accuracy of the model9 based on the 5 prognostic variables
that were included in themultivariate analysis of this work does
not exceed 62%, so the apparently improved prognosis of
patients treated with cyclophosphamide may be due to more
favorable baseline characteristics.We therefore believe that no
conclusion can be made on the grounds of the data presented
here about differences of the various treatments administered
in the third-line setting in our patient population, although a
number of hypotheses can be generated. In our series, besides
being associated with an unfavorable effect on survival with
respect to other treatments, taxane- and cisplatin-based che-
motherapy was associated with a 63% and 75% overall inci-
dence of grade 3 to 4 toxicity, respectively. In the study
mentioned above involving 45 patients receiving accelerated
MVAC after platinum-gemcitabine regimen, the median time
to progression and overall survival, respectively, were 9.6 and
16.5 months when gemcitabine-platinum was given in the
adjuvant setting (40% of patients), but only 4.4 and 5.7 months
when gemcitabine-platinumwas administered in themetastatic
settings (60% of patients). Of note, grade 3 to 4 toxicities were
reported in 31 patients (69%), with 4 sepsis-related deaths.19
Consistently with the results described in our series, these
findings suggest that platinum-based chemotherapy should be
administered early throughout the course of advanced bladder
cancer, whereas vinflunine and taxane-based chemotherapy
are valuable second-line treatment option, although only vin-
flunine has been tested in a phase III trial. Due to the radiologic
activity observed coupled with its excellent safety profile,
metronomic cyclophosphamide may be an option in the
third-line setting, if supported by adequate evidence provided
PS¼ performance status.in prospective clinical trials. Patients who are not considered fit
to receive intravenous chemotherapymay tolerate single-agent
metronomic cyclophosphamide.
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CONCLUSIONS
In the patient population of 52 patients of this retrospective
study, we showed that the median overall survival associated
with the use of third-line chemotherapy was 31 (28–36) weeks,
which suggests that third-line chemotherapy can be adminis-
tered with benefit to suitable patients. Unexpectedly, we
observed a significantly longer overall survival in patients
receiving single-agent cyclophosphamide, with few grade 3
to 4 toxicities, and a shorter survival in patients treated with
platinum-based combinations, with a high rate of grade 3 to 4
toxicities. Given the lack of any approved treatment in heavily
pretreated patients with urothelial carcinoma, further studies
should explore the efficacy of metronomic single-agent cyclo-
phosphamide, which may yield a survival benefit with low costs
and no detrimental effect on quality of life, due to its oral route
of administration and low toxicity.
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